Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Nektar TherapeuticsNASDAQ: NKTR

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow turns negative

Q2 FY2026 investing cash flow was -$399.11M, compared with $49.62M a year earlier. Trailing-twelve-month investing cash flow was -$844.4M.

Context

  • Investing cash flow amounted to 2.2% of revenue in FY2025, down 142.7 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near -$399.11M or moves back toward the trailing-twelve-month quarterly average of -$211.1M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$399.11M+13.8% QoQ
Last fiscal yearDec 2025
-$1.2M-100.8% YoY
LTMJun 2026
-$844.4M-523.0% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-904.4%——
1 year-100.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(1.2M) USD
Year-over-year change
-100.8%

Investing Cash Flow vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -523.0% is the lowest of 9, against a peer median of -14.7%.
  • Investing cash flow amounts to 1546.8% of revenue for NKTR, versus a peer median of 74.1%.
NKTR Competitors
Investing Cash Flow for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTRNektar TherapeuticsLTM Jun 2026$844.4M USD-523.0%—1546.8%
CHRSCoherus Oncology, Inc.LTM Mar 2026$423.23M USD+4102.0%—902.7%
XNCRXencor, Inc.LTM Jun 2026$197.64M USD+467.4%—188.3%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$156.89M USD+575.2%-30.6%—
IMTXImmatics N.V.LTM Mar 2026€128.77M EUR-5.5%—345.3%
MGNXMacroGenics, Inc.LTM Mar 2026$78.68M USD-158.5%—50.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M USD-67.0%—53.8%
IMCRImmunocore Holdings plcLTM Mar 2026$21.83M USD-93.7%+76.9%5.7%
IPHAInnate Pharma S.A.FY2025€7M EUR-23.9%+55.1%251.2%
ANLAdlai Nortye Ltd.LTM Jun 2024$4.81M USD——74.1%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-6.8%0.0%
Peer median (excluding NKTR) —-14.7%+24.1%74.1%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.